BioXcel Corporation
18 articles with BioXcel Corporation
-
BioXcel Therapeutics Announces Presentations at the ISBD 2021 Global Annual Conference
5/11/2021
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced that four abstracts were selected for presentation at the International Society for Bipolar Disorders 2021 Global Annual Conference, which will take place virtually from May 13-15, 2021.
-
BioXcel Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
5/10/2021
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced its quarterly results for the first quarter ended March 31, 2021 and provided an update on key strategic and operational initiatives.
-
BioXcel Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
5/4/2021
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BioXcel, will participate in two upcoming virtual healthcare investor conferences.
-
BioXcel Therapeutics Announces Presentations on SERENITY I & II at the 2021 American Psychiatric Association Annual Meeting
4/26/2021
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced that data from its two pivotal Phase 3 trials of BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II will be presented at the upcoming American Psychiatric Association Annual Meeting.
-
BioXcel Therapeutics Announces Results of Phase 1b/2 Study of BXCL501 for the Treatment of Opioid Withdrawal Symptoms
3/31/2021
BioXcel Therapeutics, Inc. announced topline results from its Phase 1b/2 proof-of-concept RELEASE study of BXCL501, the Company’s proprietary, orally dissolving thin film formulation of dexmedetomidine, for the treatment of opioid withdrawal symptoms.
-
2021 is off to a hopeful start for some companies, executives and scientists, while others are forced to fold programs and recalibrate.
-
BioXcel Therapeutics Announces Grant by U.S. Department of Defense to Evaluate BXCL501 in Patients Suffering from PTSD
12/7/2020
Grant will support clinical studies in patients with post-traumatic stress disorder related to alcohol and substance abuse
-
BioXcel Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
11/12/2020
Complete NDA submission for BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorders on track for Q1 2021
-
BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2 Trial with BXCL501 for the Treatment of Agitation Associated with DeliriumFifth potential indication for BXCL501, an orally dissolving thin film
10/26/2020
BioXcel Therapeutics, Inc. announced that its Investigational New Drug application for BXCL501, the Company’s novel, proprietary, orally dissolving, sublingual thin film formulation of dexmedetomidine, has received clearance by the Division of Psychiatry Products at the U.S.
-
BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
8/14/2020
SERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application (“NDA”) submission to U.S. Food and Drug Administration (“FDA”) planned for Q1 2021
-
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock - July 29, 2020
7/29/2020
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical development company, announced the pricing of an underwritten public offering of 4,000,000 shares of common stock at a public offering price of $50.00 per share.
-
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock - July 27, 2020
7/27/2020
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical development company, announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock.
-
BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
7/20/2020
Highly statistically significant improvements in PEC score observed vs. placebo (p<0.0001) at two hours in the SERENITY trials for both doses tested
-
BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from Delirium and Agitation
7/9/2020
Company providing BXCL501 to evaluate its activity in patients with COVID-19 that may require calming or arousable sedation following intubation
-
BioXcel Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Formulation for BXCL501 and Methods of Treating AgitationPatent is expected to extend IP protection until 2039
7/7/2020
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application No. 16/453,679 related to BXCL501, the Company’s proprietary sublingual thin-film formulation of dexmedetomidine.
-
BioXcel Therapeutics Announces Appointment of Reina Benabou, M.D., Ph.D., as Chief Development OfficerWill lead global clinical development strategy and medical affairs for the Company’s neuroscience programs
6/23/2020
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, announced the appointment of Reina Benabou, M.D., Ph.D., as Senior Vice President and Chief Development Officer.
-
BioXcel Therapeutics Announces Appointment of William P. Kane as Chief Commercial OfficerFormer Allergan Commercial Head to lead commercialization efforts for BXCL501 across multiple neuropsychiatric disorders
6/16/2020
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, announced the appointment of Will Kane as Executive Vice President and Chief Commercial Officer.
-
BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 RELEASE Trial of BXCL501 for the Treatment of Opioid Withdrawal SymptomsTopline results expected in the first quarter of 2021
6/11/2020
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, announced that the first patient has been enrolled in the Phase 1b/2 RELEASE trial of BXCL501, the Company’s proprietary sublingual thin-film formulation of dexmedetomidine, for the treatment of opioid withdrawal symptoms.